Annals of dermatology

  • 제30권6호
  • /
  • Pages.668-675
  • /
  • 2018
  • /
  • 1013-9087(pISSN)
  • /
  • 2005-3894(eISSN)
대한피부과학회 (Korean Dermatological Association)
권호 표지
DOI QR코드

DOI QR Code

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea

  • Choi, Chong Won (Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Yang, Seungkeol (Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Jo, Gwanghyun (Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Bo Ri (Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Youn, Sang Woong (Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital)
  • 투고 : 2018.05.18
  • 심사 : 2018.07.10
  • 발행 : 2018.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. Objective: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. Methods: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. Results: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904~2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients' own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088~22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient's expense (HR, 4.138; 95% CI, 1.684~10.168) was a predictor of discontinuation rather than satisfaction. Conclusion: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.

키워드

참고문헌

  1. Choi CW, Kim BR, Ohn J, Youn SW. The advantage of cyclosporine A and methotrexate rotational therapy in long-term systemic treatment for chronic plaque psoriasis in a real world practice. Ann Dermatol 2017;29:55-60. https://doi.org/10.5021/ad.2017.29.1.55
  2. Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol 2013;31:S63-S70.
  3. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-872. https://doi.org/10.1111/j.1365-2133.2012.10901.x
  4. Vilarrasa E, Notario J, Bordas X, Lopez-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol 2016;74:1066-1072. https://doi.org/10.1016/j.jaad.2016.01.037
  5. Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol 2017;76:662-669.e1. https://doi.org/10.1016/j.jaad.2016.10.033
  6. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 2016;175:340-347. https://doi.org/10.1111/bjd.14552
  7. van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lumig PP, Driessen RJ, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 2014;171:1189-1196. https://doi.org/10.1111/bjd.13087
  8. Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015;172:244-252. https://doi.org/10.1111/bjd.13343
  9. van den Reek JM, van Lumig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 2014;170:415-424. https://doi.org/10.1111/bjd.12648
  10. Nickoloff BJ, Stevens SR. What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 2006;54:S143-S151. https://doi.org/10.1016/j.jaad.2005.10.059
  11. Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology 2015;230:46-54. https://doi.org/10.1159/000366499
  12. Menter A, Thaci D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 2015;73:410-419.e6. https://doi.org/10.1016/j.jaad.2015.06.038
  13. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-1545. https://doi.org/10.1111/jdv.12046
  14. Vergou T, Moustou AE, Antoniou C. Five-year experience with ustekinumab for psoriasis: real-life data of a single centre. J Eur Acad Dermatol Venereol 2017;31:e40-e41. https://doi.org/10.1111/jdv.13658
  15. Marinas JE, Kim WB, Shahbaz A, Qiang JK, Greaves S, Yeung J. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Australas J Dermatol 2018;59:e11-e14. https://doi.org/10.1111/ajd.5_12815
  16. Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015;135:2632-2640. https://doi.org/10.1038/jid.2015.208
  17. Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges 2016;14:1089-1099. https://doi.org/10.1111/ddg.13152
  18. Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol 2016;55:296-302. https://doi.org/10.1111/ijd.12879
  19. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-2054. https://doi.org/10.1517/14656566.2011.590475